Adesso Ventures, the German Heart Center Berlin Foundation, the Brandenburg Investment Bank, and Business Angels are participating in the funding round. Noah Labs' flagship software, Ark, enables AI-powered telemonitoring of heart failure patients. Additionally, Noah Labs is leading three clinical studies on the effectiveness of voice analysis as a novel biomarker for detecting heart failure.
Noah Labs, a Berlin and Potsdam-based digital health startup focused on AI-powered telemonitoring for patients with heart failure, has successfully closed a seed funding round of €3 million. Lead investor Nina Capital from Barcelona a dedicated health technology investor. Co-investors include adesso ventures and the Foundation of the German Heart Center Berlin (DHZB). Additionally, the Brandenburg Investment Bank's ProFIT Brandenburg funding program contributes with a grant and a loan to the financing as well as a range of business angels.
Noah Labs Ark, the company's flagship software, which received approval as a Class IIa medical device under the EU Medical Device Regulation (MDR) in April, enables comprehensive remote monitoring and management of chronic diseases. Doctors can detect deterioration and risks early, which has been shown to reduce cardiovascular complications, hospitalizations, and mortality, such as in cases of heart failure. To achieve this, Noah Labs Ark monitors relevant vital parameters to assess and predict patient health. The current focus of the cardiological application is heart failure, but the software also monitors hypertension and cardiac arrhythmias. Smartwatches, ECGs, and blood pressure monitors, which are approved as medical devices, transmit the data collected from patients in real-time to the practice or clinic.
Another current research focus of Noah Labs is the development and application of AI in voice-based diagnostics of heart diseases. The company has entered into a strategic partnership with the German Heart Center of the Charité (DHZC) in Berlin. As part of a clinical study, project partners, including the Mayo Clinic in the USA, are investigating the effectiveness and potential of voice analysis as a novel, non-invasive, and early biomarker for the diagnosis and monitoring of patients with heart failure. Noah Labs' AI analyzes hundreds of parameters in the voice samples of the study participants, capturing even the smallest changes. In the long term, such a solution can help to identify changes at an early stage and thus make timely therapeutic decisions to effectively reduce hospital stays.
Noah Labs co-founder and CEO Oliver Piepenstock said, "We are proud that our high-caliber investors share our vision, which is ‘Live healthier for longer with AI-driven Care and Research’. We were eager to work together with true health tech experts who, in addition to capital, bring their expertise and networks as healthcare entrepreneurs, regulatory experts, and healthcare systems. We are especially pleased to be the first external investment of the DHZB Foundation. With the fresh capital, we will further intensify our research activities in voice analysis and develop our solutions for other medical conditions in the long term."
Marta Zanchi, founder and managing partner of Nina Capital, commented, "We were particularly impressed by Noah Labs' research-centric approach. The team is constantly exploring new possibilities and pushing the boundaries of what is possible to significantly improve the quality of life for chronic heart patients. The associated technology-driven process is absolutely convincing and makes an important pioneering contribution to scientific research. Noah Labs puts people at the center of its work, developing software and products that are intuitive, user-friendly, and accessible to everyone."
Andreas Portmann, Managing Director of the DHZB Foundation, states: "Our foundation aims to significantly improve the lives of people with cardiovascular diseases and to prevent these conditions in the future. To achieve this, we specifically support innovative projects that modernize our healthcare system and add value for patients. We are convinced that digital tools and novel voice-based biomarkers will offer a decisive advantage in cardiovascular medicine. Noah Labs has developed an exceptional technology platform for this purpose and is part of an outstanding innovation ecosystem in Berlin that truly impacts patients."
Malte Unger, Managing Partner of adesso ventures: “Noah Labs is setting new standards in the industry with its innovative AI-based voice analysis for the detection of heart failure. Together with the already successfully implemented Ark platform, the company offers a comprehensive solution to support patients with chronic heart conditions. As a tech investor with a focus on ambitious ventures, we were particularly impressed by the technological maturity and expertise of the founding team.”
About Noah Labs
At Noah Labs, our AI-powered approach to cardiovascular care and research is dedicated to helping people with cardiovascular disease live longer, healthier lives. The Noah Labs Ark cardiovascular software platform enables cardiologists to efficiently monitor patients with heart failure through telemedicine, utilizing external measurement devices such as smartwatches, blood pressure cuffs, and scales. These devices wirelessly transmit health data to the Noah Labs Ark, where it is continuously analyzed, allowing doctors to detect changes early and respond immediately.
In addition to this, we are developing innovative voice-based machine learning software designed for the early detection of decompensated heart failure - the leading cause of hospitalization. This cutting-edge technology analyzes changes in vocal tone caused by pulmonary edema and fluid accumulation, detecting deterioration up to 14 days before current standard methods. By doing so, it helps avoid costly hospitalizations. Our patented solution is undergoing testing at prestigious institutions including the Mayo Clinic in the USA, Charité in Berlin, and university hospitals in Maastricht and Barcelona.
Founded in 2021 by physician Dr. Leonhard Riehle, machine learning engineer Marcus Hott, and serial entrepreneur Oliver Piepenstock, we are an ISO 13485 certified manufacturer of software-based medical devices, currently employing 20 dedicated professionals.
noah-labs.com
About Nina Capital
Nina Capital is a specialized venture capital firm investing exclusively at the intersection of healthcare and technology. With an international outlook from our home in Europe, we seed and support need-driven founders committed to improving healthcare with the help of technology.
nina.capital
About adesso ventures
adesso ventures is a venture capital firm focused on European startups that shape the future of enterprise tech and digital health. Besides capital, adesso ventures supports its portfolio companies by leveraging adesso Group’s market access to enterprise clients across various industries and technological expertise. Since its beginning in 2022, adesso ventures partnered up with 12 startups, such as acto, Nia Health, and TamedAI.
adesso.vc
About DHZB Foundation
The DHZB Foundation is an independent, non-profit organization established by the State of Berlin to promote the significance of the capital city as an international center of excellence for cardiovascular medicine. Since its inception, the DHZB's goal has been to combine clinical excellence with education and research through close collaboration with Berlin universities and medical faculties, as well as through international exchange with leading heart centers abroad. Together with the Charité Universitätsmedizin Berlin, the DHZB Foundation operates the German Heart Center of Charité (DHZC), which is among the ten leading specialized clinics for cardiology and heart surgery worldwide.
dhzb.org/en
Contact
Oliver Piepenstock, Co-Founder and CEO Noah Labs
oliver.piepenstock@noah-labs.com
.png)
